Moving rehabilitation research forward: Developing consensus statements for rehabilitation and recovery research by Bernhardt, J et al.
 1 
 
 
Moving rehabilitation research forward: developing consensus statements for 
rehabilitation and recovery research. 
Julie Bernhardt 1,2 
Karen Borschmann 1,2 
Lara Boyd3 
S Thomas Carmichael4 
Dale Corbett5,6 
Steven C Cramer7 
Tammy Hoffmann8 
Gert Kwakkel9 
Sean Savitz10 
Gustavo Saposnik11 
Marion Walker12 
Nick Ward13, 14 
 
1Centre for Research Excellence in Stroke Rehabilitation and Recovery, Australia  
2The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia  
3Department of Physical Therapy and the Djavad Mowafaghian Centre for Brain 
Health, University of British Columbia, Canada  
4 Departments of Neurology and Neurobiology, David Geffen School of Medicine at 
UCLA, United States  
5Department of Cellular and Molecular Medicine, University of Ottawa, Canada  
6Canadian Partnership for Stroke Recovery, University of Ottawa, Canada  
7Depts. Neurology, Anatomy & Neurobiology, and Physical Medicine & Rehabilitation, 
University of California, Irvine, USA  
8Centre for Research in Evidence-Based Practice, Bond University, Robina, Queensland, 
Australia  
9Department of Rehabilitation Medicine, Neuroscience Campus Amsterdam, VU University 
Medical Centre, Amsterdam, The Netherlands  
10Department of Neurology, McGovern Medical School, UT Health, Houston, Texas, United 
States  
11Department of Medicine, University of Toronto, Canada  
12Division of Rehabilitation and Ageing, University of Nottingham, Nottingham, United 
Kingdom   
13Sobell Department of Motor Neuroscience UCL Institute of Neurology, Queen Square, 
London, United Kingdom   
14National Hospital for Neurology and Neurosurgery, Queen Square, London, United 
Kingdom  
 
Word count: 1749 
Keywords: consensus, neuro-biology, recovery, rehabilitation, recommendations, stroke 
 
 
 
 2 
 
 
 
 
ABSTRACT 
Stroke recovery is the next frontier in stroke medicine. While growth in rehabilitation and 
recovery research is exponential, a number of barriers hamper our ability to rapidly progress 
the field. Standardised terminology is absent in both animal and human research, methods 
are poorly described, recovery biomarkers are not well defined and we lack consistent 
timeframes or measures to examine outcomes. Agreed methods and conventions for 
developing, monitoring, evaluating and reporting interventions directed at improving 
recovery are lacking, and current approaches are often not underpinned by biology. We 
urgently need to better understand the biology of recovery and its time course in both 
animals and humans to translate evidence from basic science into clinical trials.  A new 
international partnership of stroke recovery and rehabilitation experts has committed to 
advancing the research agenda. In May 2016 the first Stroke Recovery and Rehabilitation 
Roundtable will be held, with the aim of achieving an agreed approach to the development, 
conduct and reporting of research. A range of methods will be used to achieve consensus in 
four priority areas: Pre-clinical recovery research; Biomarkers of recovery; Intervention 
development, monitoring and reporting and; Measurement in clinical trials. We hope to 
foster a global network of researchers committed to advancing this exciting field. Recovery 
from stroke is challenging for many survivors. They deserve effective treatments 
underpinned by our evolving understanding of brain recovery and human behaviour. 
Working together we can develop game-changing interventions to improve recovery and 
quality of life in those living with stroke. 
 
 
  
 3 
 
 
Introduction: The problem and solution 
The explosion of knowledge about the stroke-damaged brain must be incorporated into our 
collective thinking about the nature and delivery of rehabilitation and restorative therapies 
(1). Variable methodological quality of animal studies (2), poorly defined interventions (3), 
and lack of agreed methods for developing, monitoring, evaluating and reporting 
interventions limit translation of research into evidence-based therapies (4). Furthermore, 
patient descriptions are not standardised, recovery biomarkers are not well defined (5) and 
we lack agreed time-points or measures to examine outcomes in rehabilitation and recovery 
trials (6).  
By creating an international partnership of experts from a broad range of scientific and 
clinical disciplines, we aim to achieve consensus on developing, conducting and reporting 
rehabilitation and recovery research, and create a new community of practice. In this first 
roundtable, four areas we will examine represent important roadblocks to current research 
efforts. The aim of this paper is to summarise priorities for each theme.  
Theme 1: Pre-clinical recovery research: ‘Addressing the first translational gap’ 
To address the first gap in translation, we need to better translate pre-clinical evidence into 
human discovery trials in a bidirectional and iterative manner. The goal is to develop a 
deeper understanding of the neurobiology of recovery in human stroke survivors. Basic 
scientists need to understand the most pressing issues in stroke recovery and rehabilitation 
and work closely with their clinical counterparts in designing studies, taking a "Bedside to 
Bench" approach instead of the conventional "Bench to Bedside" approach. Understanding 
the biology and timing of recovery in animals and in humans requires knowledge of 
underlying molecular mechanisms that may be influenced by different therapies, such as 
rehabilitation and stem cells (5), with the potential to augment post-stroke plasticity and 
brain repair.  Methods for enhancing the potential for functional and structural plasticity in 
surviving brain and spinal cord are needed (7-9). Translation will improve by defining inter-
species differences, developing robust, pre-clinical animal models that better represent 
clinical stroke populations (older, with co-morbidities) (10) who do not recover within a few 
weeks post-stroke (11), and identifying more reliable, valid and sensitive histological and 
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behavioural outcomes (7).  Another important issue is to hold pre-clinical studies to the 
same quality standards and rigor as clinical research (12). Sample size, age groups, and 
gender differences are not often considered in pre-clinical studies, ultimately limiting their 
clinical translation (2, 13, 14). Thus, a main point of pre-clinical studies of stroke repair is to 
model human recovery.  
Theme 2: Recovery biomarkers  
A key impediment to the development of new therapies for promoting recovery after stroke 
is not knowing who or when best to treat. One of the most important findings to emerge 
from decades of work in rodents was the identification of a period of spontaneous biological 
recovery during which the effect of training is heightened (15). Investigating the 
mechanisms involved in humans would reveal exciting therapeutic targets.  A different type 
of problem, specific to human studies, is heterogeneity in the residual structural and 
functional post-stroke brain architecture and the impact this has on potential interventions 
(16, 17). The answer to ‘who and when’ is the development of biomarkers to provide 
knowledge of both therapeutic targets and prognosis in human stroke. There are limited 
validated biological markers of stroke recovery, but promising potential targets exist (5). We 
define stroke recovery biomarkers as “indicators of disease state that can be used clinically 
to reflect underlying molecular/cellular events and/or predict outcome associated with 
recovery from stroke”, which may include markers of biology (blood, genetics), imaging 
(structural, functional, chemical), neurophysiology (patterns of brain excitability or electrical 
activity), or combinations of such (1, 18, 19). While most research has explored relationships 
between late biomarkers (3-6 months post-stroke) and final stages of recovery (19, 20), 
investigation of early biomarkers (<7 days) reflecting the mechanisms of spontaneous 
biological recovery is an urgent priority. Furthermore, distinction is required between cross-
sectional measures that capture biological state, measures that predict future clinical 
events, and measures that change in parallel with behavioural change; each of these has 
value in stroke research. 
Blood biomarker analysis is viable because many brain-derived molecules cross the blood-
brain-barrier, including micro-RNA’s, lipids, short peptide chains, and exosomes. Based on 
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similar analyses from traumatic brain injury (21) and Alzheimer’s Disease (22), there is an 
expectation of identifying molecular signatures of recovery post-stroke in humans (23). 
Individuals’ genetic profiles may also influence recovery (24-26). While interest has centred 
on genes known to contribute to neuroplasticity (27), there are a number of candidate 
biomarkers to consider as well as gene-gene interactions, and epigenetics.   
Considerable attention has focused on brain imaging to define post-stroke patterns of 
recovery. Imaging is non-invasive and easily accessible, enabling categorisation of brain 
anatomy, function, chemistry and connectivity (28-31). Another potential recovery 
biomarker is neurophysiological status, mapped using non-invasive brain stimulation (i.e., 
transcranial magnetic stimulation; TMS) (19, 30). TMS based neurophysiological measures of 
the electrophysiological relationship(s) between the cortical hemispheres (32) and 
corticospinal tract integrity via the generation of motor evoked potentials relate to motor 
outcome in chronic (19, 33) and acute stroke (34). However their value in predicting 
recovery is not well understood. 
Recovery biomarker use may foster developments in new therapies and improve clinical 
trial efficiency through better patient selection or stratification. Tailoring of therapies for 
individual patients based on their capacity for neural reorganisation and recovery will 
facilitate personalised interventions, guiding the delivery of effective treatment to the right 
people, at the right time. Once identified, we must define the psychometric qualities and 
performance of proposed biomarkers at different time-points of recovery. Prediction 
models for patient subgroups would need to be validated; this would require large cohorts 
and the development of a world-wide network (35).  
Theme 3: Intervention development, monitoring and reporting  
Sequential development, testing and refining of interventions through trial phasing is less 
common in stroke rehabilitation than other areas of stroke medicine. Furthermore, the 
description of interventions in stroke rehabilitation studies is typically incomplete and 
monitoring of interventions poorly described and reported (36), leading to significant 
research waste (3).  
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The need for systematic development of complex interventions has been highlighted for 
some time and useful frameworks exist (37). To date, researchers employ various methods 
to develop interventions intended for evaluation; and many fail to describe the 
underpinning theoretical framework or intended biological mechanisms to improve 
recovery or outcomes. Dosing studies in the trial development phase are rare (38) and 
insufficient attention has been paid to how much training is needed, and when it should be 
applied to drive neurological recovery. Too often, our choice of intervention type, dose or 
scheduling is arbitrarily assigned (as reflected in many meta-analyses of stroke rehabilitation 
interventions), with a ‘more is better’ mantra that is likely too simplistic and may even be 
harmful at certain points in the recovery pathway (39). In complex behaviour change 
research, we see increased attention on co-design of interventions with the health 
consumer (40); turning these types of interventions into standardised protocols for delivery 
in trials is not simple. 
Intervention fidelity is also poorly addressed in most rehabilitation trials, with few reporting 
the methods used to monitor the delivery of interventions. While interest in the area is 
growing (41-43), establishing agreed standards for monitoring and reporting of fidelity 
would significantly improve our research. When evidence of intervention efficacy exists, 
insufficient reporting of intervention protocol is a substantial barrier to reliable 
implementation or replication of research findings, yet this has received little attention (3). 
The Template for Intervention Description and Replication (TIDieR), which provides authors 
with guidance about how to structure accounts of their interventions (44) is a step in the 
right direction.  But we must improve how we develop, monitor and report interventions. 
This will reduce research waste and, when interventions are effective, hasten translation 
into clinical practice. 
Theme 4: Measurement in clinical trials  
The number of rehabilitation trials is growing exponentially, however many (98% of physical 
therapy trials in one recent review) (45) are underpowered, single site, testing feasibility of 
an intervention or are proof-of-concept trials. Systematic reviews of rehabilitation trials are 
challenging given the high variability in outcomes used, the timing of intervention delivery 
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and outcome assessment (6). These problems are further compounded by poor reporting of 
interventions raised in Theme 3. If researchers used a core set of trial measures, gathered at 
agreed time-points after stroke, our ability to compare results across trials, pool data for 
meta-analyses or undertake individual patient meta-analyses would be vastly improved.  
Large pooled data sets from rehabilitation trials could be used to develop hypotheses about 
stroke recovery or help validate prognostic tools.  We also need to consider how we stratify 
patients in trials and whether recovery biomarkers are robust enough for that purpose 
(Theme 2). When recruitment occurs later after stroke, some measure of stroke severity at 
time of onset is critical to developing our understanding of recovery. We may need to 
consider new recruitment models that track patients from stroke onset, or retrospectively 
acquiring reliable and simple proxy measures of baseline severity. Insufficient attention has 
also been paid to systematic acquisition of pre-stroke lifestyle and other variable that are 
likely to inform stroke recovery phenotypes.  
Limitations of many measurement tools are well known and a number of frameworks exist 
to support selection of core measurements, for example the international classification of 
functioning, disability and health (ICF) model, and COSMIN (www.cosmin.nl) which provides 
criteria for evaluating psychometric properties of tools.  Importantly, we need to ensure 
that tools we adopt can measure meaningful change and can distinguish true neurological 
repair from use of adaptation strategies to achieve a goal (46). Important achievements 
would be to standardise definitions for common terms (eg recovery), time-points of 
measurement and distinguish between different types of outcomes (47).  Simply stated, our 
challenge is not just to agree a core set of measurements, but to consider what we need to 
measure and why, to improve rehabilitation and recovery trial methods (48, 49).  
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CONCLUSION 
A new partnership of around 60 leading stroke experts has committed to advancing stroke 
recovery and rehabilitation, by achieving an agreed approach on how to develop, conduct 
and report research across the four reported themes. A key issue to address is defining 
important time-points in stroke recovery, underpinned by our best understanding of 
biological processes. The next step towards developing consensus is the inaugural Stroke 
Recovery and Rehabilitation Roundtable meeting, to be held in Philadelphia, USA, in May 
2016.  Recommendations from this meeting will be pivotal for progressing stroke recovery 
and rehabilitation research, and provide impetus for development of strong international 
partnerships to tackle the challenge of improving stroke recovery.  
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